ALLO-316 is under clinical development by Allogene Therapeutics and currently in Phase I for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Metastatic Renal Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ALLO-316’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ALLO-316 overview

ALLO-316 is under development for the treatment of acute myeloid leukemia, solid tumors and metastatic clear cell renal cell carcinoma. It is developed based on TALEN gene-editing technology and Dagger platform. The therapeutic candidate comprises of allogenic T cells engineered to express chimeric antigen receptor (CAR) consisting of an anti-CD70.

Allogene Therapeutics overview

Allogene Therapeutics is a clinical stage biotechnology company that develops allogeneic T-cell (CAR T) therapies for cancer. The company’s pipeline product includes UCART19, ALLO-501, ALL0-501A, ALL0-316, ALL0-819, ALL0-605 and ALL0-715. Its ALL0-501 and ALL0-501A an off-the shelf allogeneic CAR T therapy candidate for the treatment of hematological malignancies, CD70 and DLL3 for solid tumors and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics develops products in the therapeutic areas of cancers and solid tumors. The company seeks to partner with other companies in the research and development of immuno-oncology therapies. Allogene Therapeutics is headquartered in South San Francisco, California, the US.

For a complete picture of ALLO-316’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.